The majority of basal-like breast cancers are defined triple-negative breast cancers (TNBC), as they lack the expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2/neu), making them difficult to treat [2, 3]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.